Latest news and press releases about Fortress Biotech, Inc. (FBIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases).
Price
| Price | $2.46 |
| Market Cap | $82M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.75 |
| Price / Book | 0.47 |
| EV / EBITDA | -4.81 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 13.66% |
| Return on Invested Capital | -49.97% |
| Return on Assets | 3.67% |
| Gross Margin | 62.53% |
| Operating Margin | -42.86% |
| Net Margin | 163.32% |
Related companies: ADAG · CRVO · GANX · IMUX · NTRB · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of FBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks